| Dr Andrew J Michael, MD | |
|
3855 Gaskins Rd, Henrico, VA 23233-1441 | |
| (804) 290-4278 | |
| (804) 217-6400 |
| Full Name | Dr Andrew J Michael |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 36 Years |
| Location | 3855 Gaskins Rd, Henrico, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902892201 | NPI | - | NPPES |
| 006301151 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 0101056892 (Virginia) | Primary |
| 207WX0009X | Ophthalmology - Glaucoma Specialist | 0101056892 (Virginia) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Virginia Eye Consultants Inc | 6608860978 | 49 |
News Archive
Skoltech scientists discovered new patterns in the evolution of the influenza virus. This may help predict mutations in the viral genome and ultimately help design better vaccines.
Could hormone therapy, when begun near the onset of menopause, prevent or delay the onset of atherosclerosis, more commonly called hardening of the arteries.
Celgene Corporation announced that updated results of a phase II, multi-center, randomized, double-blind, placebo-controlled, three-arm study of apremilast in adult patients with psoriatic arthritis (CC-10004-PSA-001) were presented today at the American College of Rheumatology (ACR) 2009 annual meeting in Philadelphia, PA.
Ipsen a global biopharmaceutical group, today announced that its partner Roche disclosed results of five Phase III 24-week studies for taspoglutide for type 2 diabetes at the American Diabetes Association's (ADA) 70th Annual Scientific Sessions. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.
Evotec AG today announced that via its subsidiary Develogen AG it has entered into a license and collaboration agreement with MedImmune (the global biologics unit of AstraZeneca), in the diabetes therapeutic area, with a particular focus on the regeneration of insulin producing beta cells. The license gives MedImmune exclusive access to a portfolio of research programs and represents the first deal executed by Evotec on beta cell regeneration assets and capabilities.
› Verified 9 days ago
| Entity Name | Virginia Eye Consultants Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992727820 PECOS PAC ID: 6608860978 Enrollment ID: O20040409000511 |
News Archive
Skoltech scientists discovered new patterns in the evolution of the influenza virus. This may help predict mutations in the viral genome and ultimately help design better vaccines.
Could hormone therapy, when begun near the onset of menopause, prevent or delay the onset of atherosclerosis, more commonly called hardening of the arteries.
Celgene Corporation announced that updated results of a phase II, multi-center, randomized, double-blind, placebo-controlled, three-arm study of apremilast in adult patients with psoriatic arthritis (CC-10004-PSA-001) were presented today at the American College of Rheumatology (ACR) 2009 annual meeting in Philadelphia, PA.
Ipsen a global biopharmaceutical group, today announced that its partner Roche disclosed results of five Phase III 24-week studies for taspoglutide for type 2 diabetes at the American Diabetes Association's (ADA) 70th Annual Scientific Sessions. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.
Evotec AG today announced that via its subsidiary Develogen AG it has entered into a license and collaboration agreement with MedImmune (the global biologics unit of AstraZeneca), in the diabetes therapeutic area, with a particular focus on the regeneration of insulin producing beta cells. The license gives MedImmune exclusive access to a portfolio of research programs and represents the first deal executed by Evotec on beta cell regeneration assets and capabilities.
› Verified 9 days ago
| Entity Name | Commonwealth Eye Care Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568571065 PECOS PAC ID: 0749245462 Enrollment ID: O20041122001100 |
News Archive
Skoltech scientists discovered new patterns in the evolution of the influenza virus. This may help predict mutations in the viral genome and ultimately help design better vaccines.
Could hormone therapy, when begun near the onset of menopause, prevent or delay the onset of atherosclerosis, more commonly called hardening of the arteries.
Celgene Corporation announced that updated results of a phase II, multi-center, randomized, double-blind, placebo-controlled, three-arm study of apremilast in adult patients with psoriatic arthritis (CC-10004-PSA-001) were presented today at the American College of Rheumatology (ACR) 2009 annual meeting in Philadelphia, PA.
Ipsen a global biopharmaceutical group, today announced that its partner Roche disclosed results of five Phase III 24-week studies for taspoglutide for type 2 diabetes at the American Diabetes Association's (ADA) 70th Annual Scientific Sessions. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.
Evotec AG today announced that via its subsidiary Develogen AG it has entered into a license and collaboration agreement with MedImmune (the global biologics unit of AstraZeneca), in the diabetes therapeutic area, with a particular focus on the regeneration of insulin producing beta cells. The license gives MedImmune exclusive access to a portfolio of research programs and represents the first deal executed by Evotec on beta cell regeneration assets and capabilities.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrew J Michael, MD 3855 Gaskins Rd, Henrico, VA 23233-1441 Ph: (804) 290-4278 | Dr Andrew J Michael, MD 3855 Gaskins Rd, Henrico, VA 23233-1441 Ph: (804) 290-4278 |
News Archive
Skoltech scientists discovered new patterns in the evolution of the influenza virus. This may help predict mutations in the viral genome and ultimately help design better vaccines.
Could hormone therapy, when begun near the onset of menopause, prevent or delay the onset of atherosclerosis, more commonly called hardening of the arteries.
Celgene Corporation announced that updated results of a phase II, multi-center, randomized, double-blind, placebo-controlled, three-arm study of apremilast in adult patients with psoriatic arthritis (CC-10004-PSA-001) were presented today at the American College of Rheumatology (ACR) 2009 annual meeting in Philadelphia, PA.
Ipsen a global biopharmaceutical group, today announced that its partner Roche disclosed results of five Phase III 24-week studies for taspoglutide for type 2 diabetes at the American Diabetes Association's (ADA) 70th Annual Scientific Sessions. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.
Evotec AG today announced that via its subsidiary Develogen AG it has entered into a license and collaboration agreement with MedImmune (the global biologics unit of AstraZeneca), in the diabetes therapeutic area, with a particular focus on the regeneration of insulin producing beta cells. The license gives MedImmune exclusive access to a portfolio of research programs and represents the first deal executed by Evotec on beta cell regeneration assets and capabilities.
› Verified 9 days ago
Dr. Joseph Iuorno, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3855 Gaskins Rd, Henrico, VA 23233 Phone: 804-217-6363 Fax: 804-217-6400 | |
Matthew Thomas Young, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3855 Gaskins Rd, Henrico, VA 23233 Phone: 804-217-6363 Fax: 804-217-6400 | |
Andrew D. Munro, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3855 Gaskins Rd, Henrico, VA 23233 Phone: 804-217-6363 Fax: 804-217-6400 | |
Meredith Leigh Diehl, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3855 Gaskins Rd, Henrico, VA 23233 Phone: 804-217-6363 Fax: 804-217-6400 | |
Dr. George Edward Sanborn, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2924 Emerywood Pkwy Ste 103, Henrico, VA 23294 Phone: 804-330-9303 Fax: 804-330-9302 | |
Tami Ann Flowers, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3855 Gaskins Rd, Henrico, VA 23233 Phone: 804-217-6363 Fax: 804-217-6400 |